Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 115, Issue 4, Pages E733-E742
Publisher
Proceedings of the National Academy of Sciences
Online
2018-01-09
DOI
10.1073/pnas.1717063115
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
- (2018) Jake S. O’Donnell et al. SEMINARS IN CANCER BIOLOGY
- Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity
- (2017) Yasmin Leshem et al. Cancer Immunology Research
- Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting
- (2017) Victoria M. Velazquez et al. Molecular Therapy-Methods & Clinical Development
- Tolerogenic nanoparticles to induce immunologic tolerance: Prevention and reversal of FVIII inhibitor formation
- (2016) Ai-Hong Zhang et al. CELLULAR IMMUNOLOGY
- Immunogenicity of therapeutic recombinant immunotoxins
- (2016) Ronit Mazor et al. IMMUNOLOGICAL REVIEWS
- mTOR inhibitors effects on regulatory T cells and on dendritic cells
- (2016) Giovanni Stallone et al. Journal of Translational Medicine
- Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy
- (2016) Frieder Bauss et al. Molecular Oncology
- Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles
- (2016) Takashi K. Kishimoto et al. Nature Nanotechnology
- Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins
- (2016) Antonella Antignani et al. PLoS One
- Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells
- (2016) Rosanna Mezzapelle et al. Scientific Reports
- Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo
- (2015) Ronit Mazor et al. Cellular & Molecular Immunology
- Harnessing nanoparticles for immune modulation
- (2015) Daniel R. Getts et al. TRENDS IN IMMUNOLOGY
- Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen
- (2014) Raffit Hassan et al. CANCER
- Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
- (2014) J.-I. Youn et al. JOURNAL OF IMMUNOLOGY
- Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts
- (2014) M. Onda et al. JOURNAL OF IMMUNOLOGY
- In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer
- (2014) K. Hollevoet et al. MOLECULAR CANCER THERAPEUTICS
- Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers
- (2014) C. Alewine et al. MOLECULAR CANCER THERAPEUTICS
- PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
- (2014) Zhiqiang Guo et al. PLoS One
- Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
- (2014) Roberto A. Maldonado et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
- (2013) R. Hassan et al. Science Translational Medicine
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
- (2013) M. J. Selby et al. Cancer Immunology Research
- T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
- (2013) M. V. Maus et al. Cancer Immunology Research
- Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses
- (2012) Nicolas Çuburu et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
- (2012) Robert J. Kreitman et al. JOURNAL OF CLINICAL ONCOLOGY
- Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes
- (2012) W. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine Hosts
- (2011) M. E. Mossoba et al. CLINICAL CANCER RESEARCH
- Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects
- (2010) Hiroshi Maeda BIOCONJUGATE CHEMISTRY
- The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity
- (2010) Je-In Youn et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
- (2009) R. J. Kreitman et al. CLINICAL CANCER RESEARCH
- Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies
- (2009) Robert Kreitman CURRENT PHARMACEUTICAL DESIGN
- In vivodepletion of CD4+FOXP3+Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcγRIII+phagocytes
- (2009) Yulius Y. Setiady et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
- (2008) Silvia Piconese et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
- (2008) Christine H. Chung et al. NEW ENGLAND JOURNAL OF MEDICINE
- An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes
- (2008) M. Onda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More